EUVIMEDEUVIMED entdecken
Open Access

Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study

Konstantinos Stefanakis iD, Alexander Kokkinos iD, Georgia Argyrakopoulou iD, Sofia K Konstantinidou, Stamatia Simati, Matina Kouvari iD, Ajay Kumar, Bhanu Kalra, Melina Kumar, Nikolaos Bontozoglou, Konstantina Kyriakopoulou, Christos S Mantzoros iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Konstantinos Stefanakis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Boston VA Healthcare System and Beth Israel Deaconess Medical Ce…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Glucagon. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Alexander S. Onassis Public Benefit Foundation, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the changes of circulating levels of all proglucagon‐derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment. Materials and Methods Seventeen patients with obesity or with overweight and co‐morbidities, but without diabetes, were assigned to receive once‐daily oral naltrexone/bupropion 32/360 mg ( n = 8) or once‐daily subcutaneous liraglutide 3 mg ( n = 9). Participants were assessed before treatment initiation and after 3 and 6 months on treatment. At the baseline and 3‐month visits, participants underwent a 3‐hour mixed meal tolerance test to measure fasting and postprandial levels of PGDPs, C‐peptide, hunger and satiety. Clinical and biochemical indices of metabolic function, magnetic resonance‐assessed liver steatosis and ultrasound‐assessed liver stiffness were measured at each visit.

Results

Both medications improved body weight and composition, carbohydrate and lipid metabolism, and liver fat and function. Naltrexone/bupropion produced a weight‐independent increase in the levels of proglucagon ( P < .001) and decreases in glucagon‐like peptide‐2 (GLP‐2), glucagon and the major proglucagon fragment ( P ≤ .01), whereas liraglutide markedly upregulated total glucagon‐like peptide‐1 (GLP‐1) levels in a weight‐independent manner ( P = .04), and similarly downregulated the major proglucagon fragment, GLP‐2 and glucagon ( P < .01). PGDP levels at the 3‐month visit were positively and independently correlated with improvements in fat mass, glycaemia, lipaemia and liver function, and negatively with reductions in fat‐free mass, at both the 3‐ and 6‐month visits.

Conclusions

PGDP levels in response to liraglutide and naltrexone/bupropion are associated with improvements in metabolism. Our study provides support for the administration of the downregulated members of the PGDP family as replacement therapy (e.g. glucagon), in addition to the medications currently in use that induced their downregulation (e.g. GLP‐1), and future studies should explore whether the addition of other PGDPs (e.g. GLP‐2) could offer additional benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1GlucagonHumansProglucagonLiraglutideBupropionNaltrexoneOverweightPeptidesWeight LossGlucagon-Like Peptide 2ObesityGlucagon-Like Peptides

Stichwörter der Autor:innen

GLP-1bupropionglicentinglucagonliraglutidenaltrexoneobesityoxyntomodulinproglucagon-derived peptidesweight loss

Substanzen

ProglucagonGlucagon-Like Peptide 1GlucagonLiraglutideBupropionNaltrexonePeptidesGlucagon-Like Peptide 2Glucagon-Like Peptides

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Boston VA Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • First Department of Propaedeutic Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Diabetes and Obesity Unit, Athens Medical Center, Athens, Greece.
  • Ansh Labs, Webster, Texas, USA.
  • Department of Radiology, Athens Medical Center, Athens, Greece.

ORCID-Profile: Konstantinos Stefanakis, Alexander Kokkinos, Georgia Argyrakopoulou, Matina Kouvari, Christos S Mantzoros

Förderung

  • NIDDK NIH HHS
  • Alexander S. Onassis Public Benefit Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Stefanakis, K., Kokkinos, A., Argyrakopoulou, G., Konstantinidou, S. K., Simati, S., Kouvari, M., Kumar, A., Kalra, B., Kumar, M., Bontozoglou, N., Kyriakopoulou, K., & Mantzoros, C. S. (2023). Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15141

Vancouver

Stefanakis K, Kokkinos A, Argyrakopoulou G, Konstantinidou SK, Simati S, Kouvari M, et al. Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15141

BibTeX
@article{Stefanakis2023,
  author = {Stefanakis, Konstantinos and Kokkinos, Alexander and Argyrakopoulou, Georgia and Konstantinidou, Sofia K and Simati, Stamatia and Kouvari, Matina and Kumar, Ajay and Kalra, Bhanu and Kumar, Melina and Bontozoglou, Nikolaos and Kyriakopoulou, Konstantina and Mantzoros, Christos S},
  title = {Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15141}
}
Kostenlos starten →